GlaxoSmithKline, Vir Biotechnology begin late-stage testing of experimental Covid-19 therapy

The new drug candidate is being developed for the early treatment of Covid-19 in patients who are at high risk of hospitalization.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.